Title: The results of the open observational, international, multicenter, prospective program to assess the efficacy, safety and tolerability of the first direct renin inhibitor RasilezR (aliskiren) in patients with arterial hypertension in ‘real-life’ clinical practice settings (DRIve)
Abstract: Rasilez® (aliskiren) is the first drug from direct renin inhibitors class (DRI), which is used to treat arterial hypertension. The first aim of the «DRIve» program (Open observational, international, multicenter, prospective study to assess the efficacy, safety and tolerability of the first direct renin inhibitor Rasilez® (aliskiren) in patients with arterial hypertension in a real life setting) is to collect information about the efficacy, safety and tolerability of Rasilez (aliskiren) in monotherapy or in combination with other drugs in a real life setting for 6 months of therapy. Secondary aims were to analyze the patient acceptance of therapy and additional factors determining the outcome of Rasilez treatment. The program had been holding out from October 2009 until July 2011 in 17 cities of Russia.